decisionhealth Newsletters, Coder Pink Sheets - 2025 Issue 2 (February)
Telehealth: Experts say the DEA’s latest proposed prescribing rule needs work
Subscribe or sign in to view the full article.
Article Overview
This article explains a 2025 DEA proposed rule affecting telehealth prescribing of controlled substances and summarizes reactions from telehealth and specialty policy experts. It is useful for clinicians, practice administrators, telehealth leaders, and compliance staff who need to understand the scope of the proposal, the types of providers it would affect, and the need to submit public comments.
Why This Topic Matters
The proposal could change how telehealth-based controlled-substance prescribing is handled for practices that built virtual care workflows during the COVID-19 public health emergency. Readers who follow telehealth policy, prescribing compliance, and access-to-care issues will want to understand the rule’s potential operational impact and the public comment timeline.
Article Sections
-
Proposed DEA telehealth prescribing rule
Introduces the agency’s latest proposal and the telehealth prescribing context it is intended to address. Summarizes the broad policy setting and the affected prescribing environment.
-
Experts predict administrative burden, patient impact
Reviews stakeholder concerns about registration structure, practice requirements, monitoring expectations, and operational impact. Discusses how commenters believe the proposal could affect provider workflow and patient access.
-
Look for statements you can use
Explains the public comment opportunity and points readers to stakeholder organizations that may share draft comments. Notes the deadline and the availability of the federal comment portal.
What You Will Learn
- The scope of the DEA proposal and the telehealth prescribing scenario it addresses
- Why telehealth and specialty organizations say parts of the rule need clarification
- What categories of provider requirements and monitoring expectations are drawing concern
- How the public comment process fits into the rulemaking timeline
Who Should Read This
- Physicians and other prescribers
- Telehealth program leaders
- Practice administrators
- Compliance and regulatory staff
- Medical society policy teams
- Patient access advocates
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com